Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $2.9 million.

  • Maravai Lifesciences Holdings' Capital Expenditures fell 6594.11% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.9 million, marking a year-over-year decrease of 5842.2%. This contributed to the annual value of $29.7 million for FY2024, which is 5475.72% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its Capital Expenditures stood at $2.9 million for Q3 2025, which was down 6594.11% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Capital Expenditures registered a high of $25.1 million during Q2 2023, and its lowest value of $1.3 million during Q3 2021.
  • Over the past 5 years, Maravai Lifesciences Holdings' median Capital Expenditures value was $5.7 million (recorded in 2024), while the average stood at $7.3 million.
  • In the last 5 years, Maravai Lifesciences Holdings' Capital Expenditures tumbled by 8682.98% in 2021 and then soared by 140866.95% in 2023.
  • Over the past 5 years, Maravai Lifesciences Holdings' Capital Expenditures (Quarter) stood at $5.7 million in 2021, then rose by 9.87% to $6.2 million in 2022, then surged by 170.34% to $16.8 million in 2023, then plummeted by 65.18% to $5.8 million in 2024, then plummeted by 49.97% to $2.9 million in 2025.
  • Its Capital Expenditures stands at $2.9 million for Q3 2025, versus $2.9 million for Q2 2025 and $5.2 million for Q1 2025.